Key result
Modulating NO and NOS activity emerges as a promising therapeutic target for treating cardiovascular disease.
Why the study?
Deepening understanding of the differing roles of NOS isoforms in disease has emerged, making impaired and overactive NOS activity attractive therapeutic targets in cardiovascular disease.
Modulation of nitric oxide synthase activity represents a potential therapeutic target for cardiovascular diseases.
Should not yet change CVD practice; leaves open NOS modulation as a hypothesis-generating target.
Nitric oxide (NO) plays an important and diverse signalling role in the cardiovascular system, contributing to the regulation of vascular tone, endothelial function, myocardial function, haemostasis, and thrombosis, amongst many other roles. NO is synthesised through the nitric oxide synthase (NOS)-dependent L-arginine-NO pathway, as well as the nitrate-nitrite-NO pathway. The three isoforms of NOS, namely neuronal (NOS1), inducible (NOS2), and endothelial (NOS3), have different localisation and functions in the human body, and are consequently thought to have differing pathophysiological roles. Furthermore, as we continue to develop a deepened understanding of the different roles of NOS isoforms in disease, the possibility of therapeutically modulating NOS activity has emerged. Indeed, impaired (or dysfunctional), as well as overactive (or dysregulated) NOS activity are attractive therapeutic targets in cardiovascular disease. This review aims to describe recent advances in elucidating the physiological role of NOS isoforms within the cardiovascular system, as well as mechanisms of dysfunctional and dysregulated NOS in cardiovascular disease. We then discuss the modulation of NO and NOS activity as a target in the development of novel cardiovascular therapeutics.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2023) conducted a review in Cardiovascular disease. Modulation of NO and NOS activity was evaluated. Modulation of nitric oxide and nitric oxide synthase activity represents an attractive therapeutic target for treating cardiovascular disease by addressing dysfunctional and dysregulated NOS mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: